UPDATE: Wedbush Securities Raises PT to $37 on Medifast on Growth Plan
Wedbush Securities reiterated its Outperform rating on Medifast (NYSE: MED) and raised its price target from $34 to $37.
Wedbush Securities commented, "To achieve its $1 billion target, which represents a compound annual growth rate of 23%, management targets doubling domestic sales and growing international sales to $150 million. … Given Medifast's solid revenue growth, strong cash flow generation, and improving financial outlook, we believe shares of MED should trade at an EV/ 2013E EBITDA multiple of 9x, a 10% premium to the peer group average, generating our $37 PT."
Medifast closed at $21.25 on Tuesday.
Latest Ratings for MED
|Oct 2015||Sidoti & Co.||Upgrades||Neutral||Buy|
|Mar 2015||Bank of America||Downgrades||Neutral||Underperform|
|Nov 2014||Imperial Capital||Downgrades||Outperform||In-line|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.